Halozyme Therapeutics (NASDAQ:HALO – Get Rating) will release its earnings data after the market closes on Tuesday, May 10th. Analysts expect Halozyme Therapeutics to post earnings of $0.44 per share for the quarter. Halozyme Therapeutics has set its FY 2022 guidance at $2.050-$2.200 EPS and its FY22 guidance at $2.05-2.20 EPS.
Halozyme Therapeutics (NASDAQ:HALO – Get Rating) last announced its quarterly earnings results on Tuesday, February 22nd. The biopharmaceutical company reported $0.39 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.35 by $0.04. Halozyme Therapeutics had a return on equity of 164.68% and a net margin of 90.84%. The company had revenue of $102.00 million during the quarter, compared to analysts’ expectations of $97.10 million. On average, analysts expect Halozyme Therapeutics to post $2 EPS for the current fiscal year and $3 EPS for the next fiscal year.
Halozyme Therapeutics stock traded up $0.06 during midday trading on Wednesday, hitting $41.00. 590 shares of the company’s stock were exchanged, compared to its average volume of 866,766. The company has a debt-to-equity ratio of 4.00, a quick ratio of 7.45 and a current ratio of 7.91. Halozyme Therapeutics has a 52-week low of $31.36 and a 52-week high of $48.97. The stock has a 50-day moving average price of $39.15 and a two-hundred day moving average price of $37.22. The company has a market cap of $5.65 billion, a P/E ratio of 14.91 and a beta of 1.24.
HALO has been the topic of several analyst reports. Zacks Investment Research raised shares of Halozyme Therapeutics from a “strong sell” rating to a “hold” rating and set a $37.00 price target on the stock in a report on Monday, March 14th. StockNews.com raised shares of Halozyme Therapeutics from a “hold” rating to a “buy” rating in a research note on Monday. Finally, Piper Sandler cut their price objective on shares of Halozyme Therapeutics from $43.00 to $42.00 in a report on Wednesday, February 23rd. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average price target of $47.83.
About Halozyme Therapeutics (Get Rating)
Halozyme Therapeutics, Inc operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.
- Get a free copy of the StockNews.com research report on Halozyme Therapeutics (HALO)
- What’s Next For Starbucks (NASDAQ: SBUX)?
- 3 Earnings Plays With Big Move Potential
- There Are Weeds In The Garden At Scotts Miracle-Gro
- It’s Time For FuboTV to Stand Out in the Sea of Streaming
- Landstar Systems Stock Can Bottom Down Here
Receive News & Ratings for Halozyme Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Halozyme Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.